Abstract
There have been numerous reviews on the beneficial effects and health benefits of the soybean protease inhibitor known as the Bowman-Birk Inhibitor (BBI) [1–15]. The early in vitro studies were so promising that in vivo studies were performed at a very early stage of BBI development. The results of animal carcinogenicity studies were sufficiently promising that permission to perform BBI human trials was sought. It was planned that human trials using BBI would be performed with BBI Concentrate (BBIC), a soybean extract enriched in BBI. BBIC achieved Investigational New Drug (IND) Status with the FDA in 1992, and human trials began at that time. There have been six INDs involving BBI human trial work for the following endpoints: cancer prevention (regression of a pre-malignant lesion known as oral leukoplakia), treatment of benign prostatic hyperplasia, prostate cancer detection and treatment (with measurements of prostate specific antigen levels and prostate volume, etc.), treatment of ulcerative colitis, gingivitis, or esophagitis (and/or alleviation of adverse side effects of lung cancer treatment), as described elsewhere [15]. There are numerous publications on the results from these trial areas [16–21]. In this “expert opinion”, the current status of BBI experimentation and human trials will be discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kennedy AR, Szuhaj BF, Newberne PM, Billings PC (1993) Preparation and production of a cancer chemopreventive agent, Bowman-Birk Inhibitor Concentrate. Nutr Cancer 19:281–302
Kennedy AR (1993) Overview: anticarcinogenic activity of protease inhibitors. In: Troll W, Kennedy AR (eds) Protease Inhibitors as cancer chemopreventive agents. Plenum publishing corporation, New York, pp 9–64 (Chapter)
Kennedy AR (1993) In vitro studies of anticarcinogenic protease Inhibitors In: Troll W, Kennedy AR (eds) Protease Inhibitors as cancer chemopreventive agents. Plenum publishing corporation, New York, pp 65–91 (Chapter)
Chang JD, Kennedy AR (1993) Suppression of c-myc by anticarcinogenic protease Inhibitors. In: Troll W, Kennedy AR (eds) Protease Inhibitors as cancer chemopreventive agents. Plenum Publishing corporation, New York, pp 265–280 (Chapter)
Kennedy AR (1994) Prevention of carcinogenesis by protease Inhibitors. Cancer Res 54:1999s–2005s
Kennedy AR (1993) Cancer prevention by protease Inhibitors. Prev Med 22:796–811
Kennedy AR (1995) The evidence for soybean products as cancer preventive agents. J Nutr 125:733s–743s
Kennedy AR (1998) Cancer prevention by Bowman-Birk Inhibitor Concentrate (BBIC). In: Prasad KN, Cole WC (eds) Cancer and Nutrition. IOS Press, Amsterdam, pp 93–98
Kennedy AR (1998) The Bowman-Birk Inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nut 68(suppl):1406S–1412S
Kennedy AR (1998) Chemopreventive agents: protease Inhibitors. Pharmacol Ther 78:167–209
Kennedy AR, Wan XS (2002) Biological effects of a soybean-derived protease Inhibitor, the Bowman-Birk Inhibitor. In: Descheemaeker K, Debruyne I (eds) Soy and Health 2002—Clinical evidence, dietetic applications. Garant Publishers, Apeldoorn, p 129–136
Kennedy AR (2007) Status of current human trials utilizing Bowman Birk Inhibitor Concentrate. In: Descheemaeker K. Debruyne I (eds) Proceedings of a Symposium, “Soy and Health 2006—Clinical evidence, dietetic applications”, held in Dusseldorf, Germany, October 2006; Garant Publishers, Apeldoorn, pp 73–79
Kennedy AR (2009) Protease Inhibitors. In: Knasmüller S, DeMarini DM, Johnson I, Gerhäuser C (eds) Chemoprevention of cancer and DNA damage by dietary factors, Chapter 42, Wiley, GmbH and Co, KGaA, Weinheim, pp 761–767
Kennedy AR, Wan XS (2011) Countermeasures for space radiation induced adverse effects. Adv Space Res 48:1460–1479
Kennedy AR (2006) The status of human trials utilizing Bowman-Birk Inhibitor Concentrate from soybeans. In: Sugano M (ed) Soy in health and disease prevention. CRC Press, Taylor and Francis Group LLC, Chapter 12, Boca Raton, Florida, USA, pp 207–223 (Chapter)
Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL Jr (2000) Single dose administration of Bowman-Birk Inhibitor Concentrate (BBIC) in patients with oral leukoplakia. Cancer Epidemiol Biomark Prev 9:43–47
Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL Jr (2000) Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk Inhibitor Concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6:4684–4691
Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks SHF, Wein AJ, Kennedy AR (2001) Effects of Bowman-Birk Inhibitor Concentrate in patients with benign prostatic hyperplasia. Prostate 48:16–28
Armstrong WB, Wan XS, Kennedy AR, Taylor TH, Meyskens FL (2003) Development of the Bowman-Birk Inhibitor for oral cancer chemoprevention and analysis of neu immunohistochemical staining intensity with Bowman-Birk Inhibitor Concentrate treatment. Laryngoscope 113(10):1687–1702
Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR, Ware JH (2008) Bowman-Birk Inhibitor Concentrate (BBIC): a novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci 53(1):175–180
Lin L, Mick M, Ware J, Metz J, Lustig R, Vapiwala N, Rengan R, Kennedy AR (2009) Phase I randomized double-blind placebo controlled single dose safety studies of Bowman Birk Inhibitor Concentrate. (submitted)
Bowman DE (1046) Differentiation of soybean antitryptic factors. Proc Soc Exp Biol Med 63:547–550
Birk Y (1961) Purification and some properties of a highly active Inhibitor of trypsin and α-chymotryotrypsin from soybeans. Biochim Biophys Acta 54:378–381
Morris CA, Morris LD, Kennedy AR, Sweeney HL (2005) Attenuation of skeletal muscle atrophy via protease inhibition. J Appl Physiol 99(5):1719–1727
Arbogast S, Smith J, Matuszczak Y, Hardin B, Moylan J, Smith JD, Ware J, Kennedy AR, Reid MB (2007) Bowman-Birk Inhibitor Concentrate prevents atrophy, weakness and oxidative stress in soleus muscle of lindlimb-unloaded mice. J Appl Physiol 102(3):956–964
Morris CA, Selsby JT, Morris LD, Pendrak K, Sweeney HL (2010) Bowman-Birk Inhibitor attenuates dystrophic pathology in mdx mice. J Appl Physiol 109(5):1492–1499
Gran B, Tabibzadeh N, Martin A, Ventura ES, Ware JH, Zhang G-X, Parr JL, Kennedy, AR, Rostami A (2006) The protease Inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis. Multiple Scler 12(6):688–697
Touil T, Ciric B, Ventura E, Shindler KS, Gran B, Rostami A (2008) Bowman-Birk Inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis. J Neurol Sci 27(1–2):191–202
Dai H, Ciric B, Zhang GX, Rostami A (2011) Bowman-Birk Inhibitor attenuates experimental autoimmune encephalomyelitis by delaying infiltration of inflammatory cells into the CNS. Immunol Res 51(2–3):145–152
Dai H, Ciric B, Zhang GX, Rostami A (2012) Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk Inhibitor. J Neuroimmunol 245(1–2):1–7
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Kennedy, A.R. (2013). The Health Benefits of the Bowman-Birk Inhibitor . In: Fang, E., Ng, T. (eds) Antitumor Potential and other Emerging Medicinal Properties of Natural Compounds. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6214-5_11
Download citation
DOI: https://doi.org/10.1007/978-94-007-6214-5_11
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-6213-8
Online ISBN: 978-94-007-6214-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)